Inhibrx prevails in trade secret case with I-Mab

Inhibrx Biosciences (INBX) is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma (IMAB) in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation before it, confirming the company’s adherence to high ethical standards and innovation in scientific research. I-Mab had initiated the lawsuit on March 1, 2022, alleging that Inhibrx and its Chief Scientific Officer, Brendan Eckelman, Ph.D., improperly accessed and used proprietary information related to several of I-Mab’s research projects during a prior arbitration proceeding involving I-Mab, for which Dr. Eckelman served as an expert witness. However, the jury found absolutely no basis for these claims, validating Inhibrx’s independent development processes and principled conduct in advancing its therapeutic innovations.